Oxaliplatin-Associated Neuropathy: A Review

Cersosimo, Robert J.

doi:10.1345/aph.1e319

Cited by 230 publications

(177 citation statements)

References 35 publications

(58 reference statements)

Supporting

Mentioning

161

Contrasting

Unclassified

Order By: Relevance

“…This form of neuropathy is acute and self-limited. Individuals receiving cumulative dosages of 540 mg/m 2 or more may begin to experience chronic symptoms [17]. Another study showed clinical deterioration in 31% of patients with aggravation of peripheral neuropathy peaking between 2.5 and 5.5 months following discontinuation of cisplatin [18].…”

Section: Evolutionmentioning

confidence: 99%

Chemotherapy-induced peripheral neuropathy — diagnosis, evolution and treatment

Iżycki

Niezgoda²,

Kaźmierczak³

et al. 2016

Ginekol Pol

View full text Add to dashboard Cite

Chemotherapy-induced peripheral neuropathy (CIPN) is one of the most frequent neurologic complications experienced by patients receiving antineoplastic drugs. Involvement of the peripheral nerves may have an important impact on daily activities and lead to severe impairment of the patient's quality of life (QoL). It seems to be of crucial importance to make a correct and early diagnosis of polyneuropathy and, if possible, spare the patient unnecessary suffering or loss of function. In the preceding article we have presented epidemiology, grading and pathogenesis of the toxic CIPN. The purpose of this article is to review current knowledge of diagnostic techniques, prevention and management strategies in the context of CIPN.

show abstract

Section: Evolutionmentioning

confidence: 99%

Chemotherapy-induced peripheral neuropathy — diagnosis, evolution and treatment

Iżycki

Niezgoda²,

Kaźmierczak³

et al. 2016

Ginekol Pol

View full text Add to dashboard Cite

show abstract

“…These data are broadly similar to those reported in reviews of oxaliplatin-related adverse effects. [99][100][101] Cassidy and Misset 100 state that oxaliplatin-induced neurotoxicity consists of a rapid-onset acute sensory neuropathy and late-onset cumulative sensory neuropathy that occurs after several cycles of therapy. The condition is reported to be reversible in about 75% of patients, with a median time to recovery of 13 weeks after treatment discontinuation.…”

Section: 77mentioning

confidence: 99%

The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation

Pandor¹,

Eggington²,

Paisley³

et al. 2006

Health Technol Assess

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NHS R&D HTA ProgrammeT he research findings from the NHS R&D Health Technology Assessment (HTA) Programme directly influence key decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC) who rely on HTA outputs to help raise standards of care. HTA findings also help to improve the quality of the service in the NHS indirectly in that they form a key component of the 'National Knowledge Service' that is being developed to improve the evidence of clinical practice throughout the NHS.The HTA Programme was set up in 1993. Its role is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined to include all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care, rather than settings of care.The HTA Programme commissions research only on topics where it has identified key gaps in the evidence needed by the NHS. Suggestions for topics are actively sought from people working in the NHS,...

show abstract

“…The use of the antineoplastic drug oxaliplatin for the treatment of a variety of cancers is significantly limited by the development of a painful peripheral neuropathy characterized by both an acute sensitivity to cold and lack of sensation in the hands and feet and a chronic foot/leg, hand/arm numbness [3]. It has previously been reported that oxaliplatin produces a peripheral neuropathy in rats in several well-characterized animal models with features observed in humans [5].…”

Section: Introductionmentioning

confidence: 99%

Supraspinal role of protein kinase C in oxaliplatin-induced neuropathy in rat

Norcini

Vivoli

Galeotti

et al. 2009

Pain

View full text Add to dashboard Cite

a b s t r a c tOxaliplatin is a platinum-based chemotherapy drug characterized by the development of a painful peripheral neuropathy which is reproduced in rodent animal models with features observed in humans. Our focus was to explore the alterations of intracellular second messengers at supraspinal level in oxaliplatin-induced mechanical hyperalgesia. In our experiments, chronic administration of oxaliplatin to rats induced mechanical hyperalgesia which lasted for many days. When the hyperalgesic rats were submitted to paw pressure test in the presence of selective PKC inhibitor Calphostin C supraspinally administered, hyperalgesic effect could be reversed showing that PKC activity in supraspinal brain regions is needed. Concurrently, oxaliplatin chronic treatment induced a specific upregulation of c isoforms of PKC and increased phosphorylation of c/e PKC isoforms within thalamus and PAG. Phosphorylation was reversed when PKC activity was inhibited by Calphostin C. Distinct PKC-activated MAPK pathways, including p38MAPK, ERK1/2 and JNK, were investigated in chronic oxaliplatin rat. A dramatic phosphorylation increase, Calphostin C sensitive, could be observed in thalamus and PAG for p38MAPK. These data show that, in oxaliplatin-induced neuropathy, enhanced mechanical nociception is strictly correlated with increased phosphorylation of specific intracellular mediators in PAG and thalamus brain regions pointing to a role of these supraspinal centers in oxaliplatin-induced neuropathic pain mechanism. Ó

show abstract

Oxaliplatin-Associated Neuropathy: A Review

Cited by 230 publications

References 35 publications

Chemotherapy-induced peripheral neuropathy — diagnosis, evolution and treatment

Chemotherapy-induced peripheral neuropathy — diagnosis, evolution and treatment

The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation

Supraspinal role of protein kinase C in oxaliplatin-induced neuropathy in rat

Contact Info

Product

Resources

About